2025/04/11 by Shaima Abdalla, Zary Forghany, Jin Ma +7 · 1 voice
Biochemistry, Genetics and Molecular Biology · #14-3-3 protein interactions #Protein Degradation and Inhibitors #Ubiquitin and proteasome pathways
paper · pdf · doi:10.1002/1873-3468.70040
openalex publication_date 2025/04/11 · openalex created_date 2025/04/12 · openalex updated_date 2026/07/22
The evolutionarily conserved E-Twenty-Six (ETS) family of transcription factors acts downstream of major signal transduction pathways and plays a pivotal role in tissue development and maintenance. Importantly, their function is frequently corrupted in a substantial proportion of tumour types, and they are also indispensable for angiogenic sprouting, a hallmark of cancer, which is essential for fuelling tumour enlargement and dissemination. Consequently, targeting aberrant ETS activity could potentially represent a precise and effective means by which to block tumour growth. Here, we present proof-of-principle high-throughput screens and an initial characterization of candidate hits, as a methodological and conceptual framework for the identification of novel ETS transcription factor inhibitors, which may ultimately lead to new therapeutic avenues for treating cancer.